Document Detail


MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs.
MedLine Citation:
PMID:  19223155     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Intrauterine exposure to SSRIs in late pregnancy can cause various serotonergic symptoms in the newborns. We associated the severity of these symptoms to neurotransmitter concentrations and genetic polymorphisms in the cytochrome P450, MAO-A and COMT enzymes. Altogether 20 children with prenatal exposure to citalopram or fluoxetine were genotyped. Infants with two high-activity alleles of the MAO-A gene had significantly higher serotonergic symptom scores than infants with at least one low-activity allele (mean 8.8 vs. 2.4, p=0.024). These infants had also higher cord blood DHPG concentrations (p=0.0054). Carriers of the high-activity COMT alleles had higher cord blood prolactin concentrations (p=0.044). According to our results, the higher serotonergic symptom score and cord blood DHPG concentration in rapid MAO-A metabolizers suggest that norepinephrine may modify the severity of perinatal serotonergic symptoms. The COMT 1947G>A polymorphism may affect the occurrence of respiratory distress symptoms in infants with prenatal SSRI-exposure via a mechanism involving prolactin.
Authors:
Johanna Hilli; Tuija Heikkinen; Riikka Rontu; Terho Lehtimäki; Ikuko Kishida; Eleni Aklillu; Leif Bertilsson; Tero Vahlberg; Kari Laine
Related Documents :
23023555 - Racial and ethnic disparities in infant mortality in the united states: the role of ges...
12970305 - Elevated umbilical cord ghrelin concentrations in small for gestational age neonates.
12566255 - Contribution of the umbilical cord and membranes to untrimmed placental weight.
19034065 - Risk of mortality subsequent to umbilical cord infection among newborns of southern nep...
25077835 - Complications in the first 5 years following cataract surgery in infants with and witho...
23767175 - Estimation of vascular endothelial growth factor and placental growth factor serum leve...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-02-14
Journal Detail:
Title:  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology     Volume:  19     ISSN:  1873-7862     ISO Abbreviation:  Eur Neuropsychopharmacol     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-03-30     Completed Date:  2009-06-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9111390     Medline TA:  Eur Neuropsychopharmacol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  363-70     Citation Subset:  IM    
Affiliation:
Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland. johanna.hilli@utu.fi
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Catechol O-Methyltransferase / genetics*
Child
Child, Preschool
Cytochrome P-450 Enzyme System / genetics
Depression / drug therapy
Female
Follow-Up Studies
Genetic Predisposition to Disease*
Genotype
Humans
Methoxyhydroxyphenylglycol / analogs & derivatives,  blood
Monoamine Oxidase / genetics*
Polymorphism, Genetic / genetics
Pregnancy
Pregnancy Complications / blood,  genetics
Prenatal Exposure Delayed Effects*
Prolactin / blood
Prospective Studies
Retrospective Studies
Serotonin Plasma Membrane Transport Proteins / genetics
Serotonin Syndrome / blood,  chemically induced*,  diagnosis
Serotonin Uptake Inhibitors / adverse effects*,  therapeutic use
Statistics, Nonparametric
Chemical
Reg. No./Substance:
0/SLC6A4 protein, human; 0/Serotonin Plasma Membrane Transport Proteins; 0/Serotonin Uptake Inhibitors; 3343-19-9/dihydroxyphenylethylene glycol; 534-82-7/Methoxyhydroxyphenylglycol; 9002-62-4/Prolactin; 9035-51-2/Cytochrome P-450 Enzyme System; EC 1.4.3.4/Monoamine Oxidase; EC 2.1.1.6/Catechol O-Methyltransferase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Involvement of nitrergic system in the anticonvulsant effect of the cannabinoid CB(1) agonist ACEA i...
Next Document:  Plasma Brain-Derived Neurotrophic Factor in treatment-resistant depressed patients receiving electro...